1[1]Iversen L, Fogh K, Ziboh VA, et al. Leukotriene B4 formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A4 by putative keratinocyte leukotriene A4 hydrolase[J]. J Invest Dermatol, 1993, 100(3): 293-298.
2[2]James JM, Kagey-Sobotka A, Sampson HA. Patients with severe atopic dermatitis have activated circulating basophils[J]. J Allergy Clin Immunol, 1993, 91(6): 1155-1162.
3[3]Shichijo M, Ebisawa M, Miura K, et al. Relationship between histamine release and leukotrienes production from human basophils derived from atopic dermatitis donors[J]. Int Arch Allergy Immunol, 1995, 107(4): 587-591.
4[4]Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations [J]. J Allergy Clin Immunol, 1989, 83(2 Pt 1): 450-455.
5[5]Ruzicka T, Simmet T, Peskar BA, et al. Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis[J]. J Invest Dermatol, 1986, 86(2): 105-108.
6[6]Koro O, Furutani K, Hide M, et al. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis[J]. J Allergy Clin Immunol, 1999, 103(4): 663-670.
7[7]Sansom JE, Taylor GW, Dollery CT, et al. Urinary leukotriene E4 levels in patients with atopic dermatitis [J]. Br J Dermatol,1997, 136(5): 790-791.
8[8]Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G, et al. Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermtitis syndrome. Relation to clinical status[J]. Allergy,2002, 57(8): 732-736.
9[9]Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate -to -severe atopic dermtitis of adults[J].Eur J Dermatol, 2001,11(3): 209-213.
10[10]Chari S, Clark-Loeser L, Shupack J, et al. A role for leukotriene antagonists in atopic dermatitis?[J]. Am J Clin Dermatol, 2001, 2(1): 1-6.
